Want to see COGT full AI Analyst Report?

Cogent Biosciences (COGT) Price & Analysis

739 Followers

COGT Stock Chart & Stats

$36.80

-$0.48(-1.19%)

At close: Jul 24 4:00 PM EDT

$36.80

-$0.48(-1.19%)

Day’s Range― - ―

52-Week Range$13.78 - $43.73

Previous CloseN/A

Volume1.59M

Average Volume (3M)2.27M

Market Cap

$5.55B

Enterprise Value$6.14B

Total Cash (Recent Filing)$792.30M

Total Debt (Recent Filing)$244.26M

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Nov 10, 2026

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.31

Shares Outstanding173,524,980

10 Day Avg. Volume2,322,531

30 Day Avg. Volume2,273,812

Financial Highlights & Ratios

PEG Ratio1.44

Price to Book (P/B)8.99

Price to Sales (P/S)0.00

P/FCF Ratio-21.50

Enterprise Value/Market Cap1.10

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.63K

Enterprise Value/Ebitda-16.48

Forecast

1Y Price Target

$54.88

Price Target Upside49.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-2.22

Revenue Forecast (FY)$5.98M

Bulls Say, Bears Say

Bulls Say

Manufacturing ReadinessThe long-term supply agreement improves operational preparedness for bezuclastinib by securing manufacturing capacity under a structured framework. Rolling forecasts and declining minimum purchase obligations provide flexibility as the candidate progresses through regulatory and potential commercial stages.

Targeted PipelineA pipeline focused on genetically defined cancers and mast cell-driven diseases gives Cogent a clearly targeted development strategy rather than a broad, unfocused portfolio. Lead programs in KIT-driven conditions provide a consistent scientific and commercial focus for future clinical progress.

Capital-raising CapacityThe authorized ATM facility gives Cogent a flexible mechanism to raise capital over time and continue funding development activities. This can extend financial resources and support execution across clinical programs, although the eventual financing impact depends on how much stock is issued.

Bears Say

Pre-revenue LossesCogent remains pre-revenue while losses continue to expand, leaving the company without commercial income to offset development spending. The worsening loss trajectory increases dependence on external financing and makes future financial performance highly dependent on clinical and regulatory progress.

Heavy Cash BurnSustained operating and free-cash-flow deficits materially reduce the resources available to fund the business internally. The worsening burn trend increases the need for additional financing and can constrain development flexibility if programs require more capital than planned.

Rising LeverageHigher debt alongside declining equity indicates increasing balance-sheet pressure while the company is still generating substantial losses. Greater reliance on leverage can reduce financial flexibility, add repayment obligations, and increase the consequences of continued cash burn.

Cogent Biosciences News

Cogent Biosciences Earns Buy Rating as Bezuclasnib Advances Toward 2027 PDUFA and Multiple 2026 Catalysts; $55 Price Target Reaffirmed

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences and keeping the price target...

1M ago

COGT

Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application

Cogent Biosciences (COGT) announced that the FDA has accepted its new drug application for bezuclastinib in patients with...

1M ago

COGT

Cogent Biosciences added to Analyst Focus List at JPMorgan

JPMorgan analyst Anupam Rama added Cogent Biosciences (COGT) to the firm’s Analyst Focus List while keeping an Overweight...

2M ago

COGT

Cogent Biosciences Secures Long-Term Bezuclastinib Supply Deal

The latest announcement is out from Cogent Biosciences ( ($COGT) ). On September 1, 2026, Cogent Biosciences entered...

2M ago

COGT

Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cogent Biosciences, with...

2M ago

COGT

Cogent’s Q2 results broadly in line with expectations, says H.C. Wainwright

Cogent’s Q2 results were broadly in line with expectations, with higher-than-expected operating expenses driving a lower FY26 EPS...

2M ago

COGT

Cogent Biosciences price target raised to $55 from $52 at Piper Sandler

Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on Cogent Biosciences (COGT) to $55 from...

2M ago

COGT

Cogent Biosciences price target raised to $52 from $45 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Cogent Biosciences (COGT) to $52 from $45 and...

2M ago

COGT

Cogent Biosciences Announces $400 Million ATM Offering

An update from Cogent Biosciences ( ($COGT) ) is now available. On August 10, 2026, Cogent Biosciences filed...

3M ago

COGT

Regulatory Catalysts and Launch Readiness for Bezuclasitinib Underpin Sam Slutsky’s Buy Rating on Cogent Biosciences

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of...

3M ago

COGT

COGT Earnings this Week: How Will it Perform?

Cogent Biosciences, Inc. (COGT) is scheduled to report 2nd quarter earnings on 08/11/2026. Regarding Q2 estimates, Wall Street...

3M ago

COGT

Cogent Biosciences submits bezuclastinib NDA to FDA

Cogent Biosciences (COGT) announced it has submitted its new drug application, or NDA, to the FDA for bezuclastinib...

4M ago

COGT

Cogent Biosciences Shareholders Back Board, Governance Proposals

Cogent Biosciences ( ($COGT) ) has shared an update. At its recent Annual Meeting, Cogent Biosciences shareholders elected...

5M ago

COGT

Cogent Biosciences announces data from analysis of PEAK Phase 3 trial

Cogent Biosciences (COGT) announced detailed clinical data from the primary analysis of the PEAK Phase 3 trial of...

5M ago

COGT

COGT FAQ

What was Cogent Biosciences’s price range in the past 12 months?

Cogent Biosciences lowest stock price was $13.78 and its highest was $43.73 in the past 12 months.

What is Cogent Biosciences’s market cap?

Cogent Biosciences’s market cap is $5.55B.

When is Cogent Biosciences’s upcoming earnings report date?

Cogent Biosciences’s upcoming earnings report date is Nov 10, 2026 which is in 12 days.

How were Cogent Biosciences’s earnings last quarter?

Cogent Biosciences released its earnings results on Aug 10, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.555 by $0.035.

Is Cogent Biosciences overvalued?

According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cogent Biosciences pay dividends?

Cogent Biosciences does not currently pay dividends.

What is Cogent Biosciences’s EPS estimate?

Cogent Biosciences’s EPS estimate is -0.56.

How many shares outstanding does Cogent Biosciences have?

Cogent Biosciences has 173,524,980 shares outstanding.

What happened to Cogent Biosciences’s price movement after its last earnings report?

Cogent Biosciences reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.555. Following the earnings report the stock price went down -2.029%.

Which hedge fund is a major shareholder of Cogent Biosciences?

Currently, no hedge funds are holding shares in COGT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cogent Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-72.57%

Trailing 12-Months

Asset Growth

203.67%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Cogent Biosciences (COGT) Earnings & Revenues

Historic Earnings Reports

COGT Stock 12 Month Forecast

Average Price Target

$54.88

▲(49.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","38":"$38","63":"$63","25.5":"$25.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,25.5,38,50.5,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.59,33.92923076923077,36.26846153846154,38.60769230769231,40.94692307692308,43.28615384615385,45.62538461538462,47.964615384615385,50.30384615384615,52.643076923076926,54.9823076923077,57.321538461538466,59.66076923076923,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.59,33.38115384615384,35.17230769230769,36.96346153846154,38.754615384615384,40.54576923076923,42.33692307692308,44.12807692307692,45.919230769230765,47.71038461538461,49.50153846153846,51.292692307692306,53.08384615384615,{"y":54.875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.59,32.621538461538464,33.653076923076924,34.684615384615384,35.716153846153844,36.747692307692304,37.77923076923077,38.81076923076923,39.84230769230769,40.87384615384615,41.90538461538462,42.93692307692308,43.96846153846154,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.76,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.48,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.93,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.68,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.59,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >